Zai Lab Limited

Hello, ladies and gentlemen. Thank you for standing by. And welcome to XyLab's full year 2023 financial results conference call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Christine Cho, Senior Vice President of Investor Relations, please go ahead.

Thank you, operator. Good morning, good evening, and welcome to XyLab's full year 2023 earnings call. Today's call will be led by Dr. Samantha Du, XyLab's founder, CEO, and chairperson. She will be joined by Josh Smiley, President and Chief Operating Officer, Dr. Rafael Motto, President and Head of Global Oncology Research and Development, Dr. Harold Reinhart, President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, and Dr. Yajing Chen, Chief Financial Officer. Jonathan Wang, our Chief Business Officer, will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. We will also refer to product revenue growth rates on a constant exchange rate basis, which is a non-GAAP financial measure. Please refer to our earnings release furnished with the SEC on February 27, 2024, for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.

Thank you, Christine. In 2023, we had another year of significant achievements for Xilat. We grew our top line by 31% on a constant exchange rate basis. We progressed several key late-stage programs. We added new global assets into our pipeline. Today, we're in a fundamentally stronger position than we have ever been with a growing base of revenues, a path to profitability, and a strong balance sheet with over 800 million USD in cash. We're now entering a period of high growth, and we are focused on three key corporate objectives to substantially grow revenues, achieve profitability, and build our global pipeline. Late last year, we launched VidGuard, and it's already off to an excellent start with sales expected to exceed 70 million USD this year in GMG. Beyond this, we have a series of other potential approvals, including Ripple Tractonate and Sodor later this year, followed by a series of other new product syndications. including Ascotizumab in CIDP, Bimatuzumab, and CAR-CT. Each of these products have the potential to meaningfully enhance the growth of our business. We are also already deeply committed to building our global pipeline by adding new assets to both our internal discovery efforts and external opportunities. And I look forward to providing updates on our progress in this regard throughout the year. And of course, we maintain disciplined capital allocation practices as we strive to achieve profitability. As we execute on these corporate objectives, we expect to deliver value, not only to patients, but also to our shareholders. Thank you for your support. as we continue on our journey of innovation and growth together. And with that, I'll pass the call over to Josh. Josh.